Overactive Bladder (OAB) Therapeutics

Global Market Trajectory & Analytics

MCP-6499

EXECUTIVE ENGAGEMENTS

POOL

3014
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

543
Interactions with Platform & by Email

PARTICIPANTS

92
Unique # Participated

VALIDATIONS

26
Responses Validated*

COMPANIES

34
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

108

PAGES

172

EDITION

19

PRICE

USD 5450

CODE

MCP-6499


COMPETITIVE METRICS

COMPANY

D S N T

% *

Astellas Pharma US, Inc.

Login Required

Astellas Pharma, Inc.

Login Required

Dr. Reddy`s Laboratories Ltd.

Login Required

Eli Lilly and Company

Login Required

Endo International PLC

Login Required

Endo Pharmaceuticals, Inc.

Login Required

Japan Tobacco, Inc.

Login Required

Novartis International AG

Login Required

Novartis Pharmaceuticals Corporation

Login Required

Pfizer, Inc.

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 34 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Overactive Bladder (OAB) Therapeutics estimated at US$3.2 Billion in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at aCAGR of 0.9% over the period 2020-2027. Anticholinergic Agents, one of the segments analyzed in the report, is projected to record 0.7% CAGR and reach US$2.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Beta-3 Adrenoreceptor Agonists segment is readjusted to a revised 1.4% CAGR for the next 7-year period.
The Overactive Bladder (OAB) Therapeutics market in the U.S. is estimated at US$865.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$621.7 Million by the year 2027 trailing a CAGR of 2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -0.2% and 0.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.1% CAGR.

SELECT PLAYERS

Allergan PLC; Astellas Pharma, Inc.; Dr. Reddy's Laboratories Ltd.; Eli Lilly and Company; Endo Pharmaceuticals, Inc.; Hisamitsu Pharmaceutical Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Recordati SpA; Speciality European Pharma Ltd.; Sunovion Pharmaceuticals, Inc.

SEGMENTS

» Drug Class (Anticholinergic Agents, and Beta-3 Adrenoreceptor Agonists)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Anticholinergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Anticholinergic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anticholinergic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Beta-3 Adrenoreceptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Beta-3 Adrenoreceptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Beta-3 Adrenoreceptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
SPAIN
Spain Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
RUSSIA
Russia Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
AUSTRALIA
Australia Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
INDIA
India Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
SOUTH KOREA
South Korea Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
LATIN AMERICA
Latin America Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
ARGENTINA
Argentina Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
BRAZIL
Brazil Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
MEXICO
Mexico Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
REST OF LATIN AMERICA
Rest of Latin America Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
MIDDLE EAST
Middle East Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
IRAN
Iran Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
ISRAEL
Israel Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
SAUDI ARABIA
Saudi Arabia Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
UNITED ARAB EMIRATES
UAE Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
REST OF MIDDLE EAST
Rest of Middle East Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
AFRICA
Africa Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Overactive Bladder (OAB) Therapeutics by Drug Class - Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Overactive Bladder (OAB) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Agents and Beta-3 Adrenoreceptor Agonists for the Years 2012, 2020 & 2027
Total Companies Profiled: 34

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com